Novavax Historical Balance Sheet

0A3S Stock

11.90 3.35 39.18%

Trend analysis of Novavax balance sheet accounts such as Total Current Liabilities of 3 B, Other Liabilities of 223.4 M or Accounts Payable of 261.4 M provides information on Novavax's total assets, liabilities, and equity, which is the actual value of Novavax to its prevalent stockholders. By breaking down trends over time using Novavax balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Novavax Inventory

25.06 Million

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.

About Novavax Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Novavax at a specified time, usually calculated after every quarter, six months, or one year. Novavax Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Novavax and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Novavax currently owns. An asset can also be divided into two categories, current and non-current.

Novavax Balance Sheet Chart

At this time, Novavax's Other Current Liabilities is comparatively stable compared to the past year. Total Current Liabilities is likely to gain to about 3 B in 2024, despite the fact that Retained Earnings are likely to grow to (3.7 B).

Other Current Liab Total Current Liabilities Other Liab Accounts Payable

Total Current Liabilities

Total Current Liabilities is an item on Novavax balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Novavax are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Novavax obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Novavax are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Novavax's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Novavax current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.At this time, Novavax's Other Current Liabilities is comparatively stable compared to the past year. Total Current Liabilities is likely to gain to about 3 B in 2024, despite the fact that Retained Earnings are likely to grow to (3.7 B).

	2021	2022	2023	2024 (projected)
Total Current Liabilities	2.4B	2.5B	2.8B	3.0B
Other Current Liabilities	1.4B	1.3B	1.5B	1.5B

Total Current Liabilities Other Current Liab

Novavax balance sheet Correlations

	Other Current Liab	Total Current Liabilities	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Other Current Assets	Other Stockholder Equity	Total Current Assets	Common Stock	Property Plant Equipment	Net Receivables	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Cash	Long Term Debt	Cash And Short Term Investments	Good Will	Short Term Investments	Capital Surpluse	Total Liab	Treasury Stock	Intangible Assets	Inventory
Other Current Liab		1.0	0.99	-0.73	-0.98	0.96	0.98	0.62	0.29	0.9	-0.58	0.96	0.59	-0.66	-0.66	-0.66	-0.66	-0.66	-0.66	-0.66	-0.66	-0.66	-0.66	0.66	-0.66	0.78
Total Current Liabilities	1.0		0.99	-0.74	-0.98	0.98	0.99	0.64	0.28	0.88	-0.59	0.98	0.54	-0.69	-0.69	-0.69	-0.69	-0.69	-0.69	-0.69	-0.69	-0.69	-0.69	0.68	-0.69	0.81
Other Liab	0.99	0.99		-0.82	-0.96	0.97	0.99	0.55	0.15	0.83	-0.54	0.95	0.47	-0.7	-0.7	-0.7	-0.7	-0.7	-0.7	-0.7	-0.7	-0.7	-0.7	0.69	-0.7	0.82
Net Tangible Assets	-0.73	-0.74	-0.82		0.73	-0.73	-0.77	-0.11	0.4	-0.47	0.3	-0.66	-0.04	0.51	0.51	0.51	0.51	0.51	0.51	0.51	0.51	0.51	0.51	-0.53	0.51	-0.73
Retained Earnings	-0.98	-0.98	-0.96	0.73		-0.96	-0.97	-0.65	-0.31	-0.91	0.65	-0.95	-0.57	0.56	0.56	0.56	0.56	0.56	0.56	0.56	0.56	0.56	0.56	-0.59	0.56	-0.82
Accounts Payable	0.96	0.98	0.97	-0.73	-0.96		0.98	0.67	0.23	0.82	-0.58	0.99	0.4	-0.75	-0.75	-0.75	-0.75	-0.75	-0.75	-0.75	-0.75	-0.75	-0.75	0.75	-0.75	0.89
Other Assets	0.98	0.99	0.99	-0.77	-0.97	0.98		0.58	0.19	0.84	-0.63	0.97	0.47	-0.71	-0.71	-0.71	-0.71	-0.71	-0.71	-0.71	-0.71	-0.71	-0.71	0.71	-0.71	0.84
Other Current Assets	0.62	0.64	0.55	-0.11	-0.65	0.67	0.58		0.73	0.78	-0.3	0.73	0.49	-0.3	-0.3	-0.3	-0.3	-0.3	-0.3	-0.3	-0.3	-0.3	-0.3	0.49	-0.3	0.66
Other Stockholder Equity	0.29	0.28	0.15	0.4	-0.31	0.23	0.19	0.73		0.58	-0.27	0.33	0.77	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	-0.02	0.03	0.02
Total Current Assets	0.9	0.88	0.83	-0.47	-0.91	0.82	0.84	0.78	0.58		-0.59	0.85	0.78	-0.34	-0.34	-0.34	-0.34	-0.34	-0.34	-0.34	-0.34	-0.34	-0.34	0.5	-0.34	0.67
Common Stock	-0.58	-0.59	-0.54	0.3	0.65	-0.58	-0.63	-0.3	-0.27	-0.59		-0.58	-0.5	0.34	0.34	0.34	0.34	0.34	0.34	0.34	0.34	0.34	0.34	-0.35	0.34	-0.44
Property Plant Equipment	0.96	0.98	0.95	-0.66	-0.95	0.99	0.97	0.73	0.33	0.85	-0.58		0.46	-0.74	-0.74	-0.74	-0.74	-0.74	-0.74	-0.74	-0.74	-0.74	-0.74	0.73	-0.74	0.86
Net Receivables	0.59	0.54	0.47	-0.04	-0.57	0.4	0.47	0.49	0.77	0.78	-0.5	0.46		-0.06	-0.06	-0.06	-0.06	-0.06	-0.06	-0.06	-0.06	-0.06	-0.06	0.07	-0.06	0.07
Total Assets	-0.66	-0.69	-0.7	0.51	0.56	-0.75	-0.71	-0.3	0.03	-0.34	0.34	-0.74	-0.06		1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	-0.8	1.0	-0.57
Short Long Term Debt Total	-0.66	-0.69	-0.7	0.51	0.56	-0.75	-0.71	-0.3	0.03	-0.34	0.34	-0.74	-0.06	1.0		1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	-0.8	1.0	-0.57
Total Stockholder Equity	-0.66	-0.69	-0.7	0.51	0.56	-0.75	-0.71	-0.3	0.03	-0.34	0.34	-0.74	-0.06	1.0	1.0		1.0	1.0	1.0	1.0	1.0	1.0	1.0	-0.8	1.0	-0.57
Cash	-0.66	-0.69	-0.7	0.51	0.56	-0.75	-0.71	-0.3	0.03	-0.34	0.34	-0.74	-0.06	1.0	1.0	1.0		1.0	1.0	1.0	1.0	1.0	1.0	-0.8	1.0	-0.57
Long Term Debt	-0.66	-0.69	-0.7	0.51	0.56	-0.75	-0.71	-0.3	0.03	-0.34	0.34	-0.74	-0.06	1.0	1.0	1.0	1.0		1.0	1.0	1.0	1.0	1.0	-0.8	1.0	-0.57
Cash And Short Term Investments	-0.66	-0.69	-0.7	0.51	0.56	-0.75	-0.71	-0.3	0.03	-0.34	0.34	-0.74	-0.06	1.0	1.0	1.0	1.0	1.0		1.0	1.0	1.0	1.0	-0.8	1.0	-0.57
Good Will	-0.66	-0.69	-0.7	0.51	0.56	-0.75	-0.71	-0.3	0.03	-0.34	0.34	-0.74	-0.06	1.0	1.0	1.0	1.0	1.0	1.0		1.0	1.0	1.0	-0.8	1.0	-0.57
Short Term Investments	-0.66	-0.69	-0.7	0.51	0.56	-0.75	-0.71	-0.3	0.03	-0.34	0.34	-0.74	-0.06	1.0	1.0	1.0	1.0	1.0	1.0	1.0		1.0	1.0	-0.8	1.0	-0.57
Capital Surpluse	-0.66	-0.69	-0.7	0.51	0.56	-0.75	-0.71	-0.3	0.03	-0.34	0.34	-0.74	-0.06	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0		1.0	-0.8	1.0	-0.57
Total Liab	-0.66	-0.69	-0.7	0.51	0.56	-0.75	-0.71	-0.3	0.03	-0.34	0.34	-0.74	-0.06	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0		-0.8	1.0	-0.57
Treasury Stock	0.66	0.68	0.69	-0.53	-0.59	0.75	0.71	0.49	-0.02	0.5	-0.35	0.73	0.07	-0.8	-0.8	-0.8	-0.8	-0.8	-0.8	-0.8	-0.8	-0.8	-0.8		-0.8	0.77
Intangible Assets	-0.66	-0.69	-0.7	0.51	0.56	-0.75	-0.71	-0.3	0.03	-0.34	0.34	-0.74	-0.06	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	-0.8		-0.57
Inventory	0.78	0.81	0.82	-0.73	-0.82	0.89	0.84	0.66	0.02	0.67	-0.44	0.86	0.07	-0.57	-0.57	-0.57	-0.57	-0.57	-0.57	-0.57	-0.57	-0.57	-0.57	0.77	-0.57

Click cells to compare fundamentals

Novavax Account Relationship Matchups

Novavax balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	1.7M	278.3M	1.4B	1.3B	1.5B	1.5B
Total Current Liabilities	25.8M	579.7M	2.4B	2.5B	2.8B	3.0B
Other Liab	12.6M	3.4M	175.5M	185.0M	212.8M	223.4M
Net Tangible Assets	(242.8M)	486.1M	(483.2M)	(760.4M)	(684.4M)	(650.1M)
Retained Earnings	(1.4B)	(1.9B)	(3.6B)	(4.3B)	(3.8B)	(3.7B)
Accounts Payable	2.9M	54.3M	127.1M	216.5M	249.0M	261.4M
Other Assets	7.5M	5.4M	24.3M	28.5M	32.7M	34.4M
Other Current Assets	7.3M	103.5M	56.1M	86.7M	99.7M	58.3M
Other Stockholder Equity	(12.5M)	7.0M	(1.4M)	(6.4M)	(7.3M)	(7.7M)
Total Current Assets	97.2M	1.2B	2.2B	1.7B	2.0B	1.0B
Common Stock	324K	714K	764K	868K	781.2K	813.2K
Property Plant Equipment	11.4M	187.7M	265.9M	400.5M	460.6M	483.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Novavax Stock Analysis

When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC